In the current DAA era, organs from HCV-viremic individuals represent an underused resource and prospective multicenter studies are urgently needed to evaluate not only the transplantation of HCV-viremic organs into non viremic recipients, but also the criteria for acceptable graft fibrosis, provided that antiviral treatment is started very early post-LTx.
HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?
Tandoi F;
2017-01-01
Abstract
In the current DAA era, organs from HCV-viremic individuals represent an underused resource and prospective multicenter studies are urgently needed to evaluate not only the transplantation of HCV-viremic organs into non viremic recipients, but also the criteria for acceptable graft fibrosis, provided that antiviral treatment is started very early post-LTx.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
